Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.

ingentiumby ingentium

In Coronavirus Literature.

Publication date: Jun 27, 2023

In the Republic of Korea (Korea), the NVX-CoV2373 (Novavax) coronavirus disease 2019 (COVID-19) vaccination was administered to 18-year-olds and over from February 14, 2022. This study sought to assess the frequency and severity of reported adverse events following the Novavax COVID-19 vaccination in Korea. Adverse events based on two national vaccine safety data were analyzed; the COVID-19 vaccination management system (CVMS) and the text-message survey (TMS). CVMS identified that the reporting rate of adverse events per 100,000 doses were lower after booster doses (84. 0) than after dose 1 (254. 6) or dose 2 (272. 9); and in 65-year-olds and over (83. 4) than in 18- to 64-year-olds (168. 1). The TMS found that local and systemic adverse events were lower in 65-year-olds and over than in 18- to 64-year-olds (p

Open Access PDF

Concepts Keywords
18years COVID-19
Coronavirus COVID-19 vaccines
February Pharmacovigilance
Koreans Safety
Surveillance Vaccination

Semantics

Type Source Name
disease VO NVX-CoV2373
disease VO COVID-19 vaccine
disease MESH coronavirus disease 2019
disease VO vaccination
disease VO frequency
disease VO vaccine
drug DRUGBANK Tilmicosin
disease VO dose
drug DRUGBANK Coenzyme M
disease IDO history
disease VO effective
disease MESH infection
disease VO organization
disease VO immunization
disease VO unvaccinated
disease MESH death
disease VO injection
disease IDO site
disease MESH anaphylaxis
disease MESH sequelae
disease MESH joint pain
disease MESH chest pain
disease MESH causality
disease MESH emergency
disease VO adverse event
disease VO vaccine dose
disease VO USA
disease MESH Allergic reactions
disease MESH Cellulitis
disease MESH Lymphadenitis
disease MESH Arthritis
disease MESH uterine bleeding
disease MESH Abscess
disease MESH Guillain Barre syndrome
disease MESH Encephalopathy
disease MESH encephalitis
disease MESH reactive arthritis
disease MESH Acute kidney injury
disease MESH syndrome
disease MESH Convulsions
disease MESH myocarditis
disease MESH phlebothrombosis
disease MESH thrombosis
disease MESH thrombocytopenia
disease VO Ad26.COV2.S

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *